Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular and Clinical Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9450 Online ISSN: 2049-9469
Journal Cover
June-2016 Volume 4 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
June-2016 Volume 4 Issue 6

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Case Report

Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report

  • Authors:
    • Misato Ueda
    • Michinori Yasuda
    • Yoshie Shibaoka
    • Ichiro Kurokawa
    • Ayako Kakuno
    • Airo Tsubura
  • View Affiliations / Copyright

    Affiliations: Department of Plastic and Reconstructive Surgery, Meiwa Hospital, Nishinomiya, Hyogo 663‑8186, Japan, Department of Dermatology, Meiwa Hospital, Nishinomiya, Hyogo 663‑8186, Japan, Department of Pathology, Meiwa Hospital, Nishinomiya, Hyogo 663‑8186, Japan, Department of Pathology, Kansai Medical University, Nishinomiya, Hyogo 663‑8186, Japan
  • Pages: 986-988
    |
    Published online on: March 28, 2016
       https://doi.org/10.3892/mco.2016.834
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Cytokeratin 19 fragment 21-1 (CYFRA21‑1) is a marker of lung cancer useful for evaluating clinical diagnosis and prognosis. To the best of our knowledge, there have been no reports of cutaneous squamous cell carcinoma (SCC) with high levels of CYFRA21‑1 to date. We herein report a case of a 79‑year‑old man with a large subcutaneous tumor of the left shoulder, which was diagnosed as primary cutaneous poorly differentiated SCC. The tumor nests were composed of poorly differentiated atypical squamous cells exhibiting high‑grade malignancy and mitotic figures; multinuclear cells were also identified inside lymph vessels. Keratin 19 (K19) was intensely expressed in tumor cells. A significantly elevated level of CYFRA21‑1 (33 ng̸ml) was observed preoperatively. After surgery, the level of CYFRA21‑1 was significantly decreased (from 33 to 5.0 ng/ml). Our case demonstrated that K19‑positive primary cutaneous undifferentiated SCC induced high levels of CYFRA21‑1 in the serum. Thus, CYFRA 21‑1 may be a marker indicative of poorly differentiated cutaneous SCC exhibiting K19 expression.

Introduction

Cytokeratin 19 fragment 21-1 (CYFRA21-1) is a circulating soluble fragment of keratin 19 (K19) (1). CYFRA21-1 is a marker of lung cancer useful for evaluating clinical diagnosis and prognosis (2). However, to the best of our knowledge, no previous cases of cutaneous squamous cell carcinoma (SCC) with high levels of CYFRA21-1 have been reported to date.

We herein report a case of K19-positive cutaneous SCC with elevated CYFRA 21-1 levels.

Case report

A 79-year-old man presented to our hospital (Meiwa Hospital, Nishinomiya, Japan) with a large subcutaneous tumor on the left shoulder. The patient's past medical history included duodenal ulcer, appendicitis, liver cirrhosis and hepatitis C. One month prior to the first visit, the patient noticed a tumor on the left shoulder exhibiting rapid growth. On clinical examination at the first visit, the tumor was solid, sized 16×10×5 cm, with a cauliflower-like appearance and accompanying hemorrhage, necrosis and ulcerations (Fig. 1).

Figure 1.

Clinical examination at the first visit revealed a large cauliflower-like solid tumor on the left shoulder, sized 16×10×5 cm, exhibiting hemorrhage, necrosis and ulcerations.

The laboratory findings included elevated white blood cell count (13,100/µl) with a left shift, with 86% neutrophils, and anemia (hemoglobin 5.7 g/dl). Three months prior to the first visit, the hemoglobin concentration was 10.0 g/dl.

An elevated C-reactive protein level was also found (6.90 mg/dl). The levels of carcinoembryonic antigen (3.4 ng/ml) and SCC antigen (1.7 ng/ml) were within normal limits. However, the level of CYFRA21-1 was significantly elevated (33 ng/ml).

Enhanced magnetic resonance imaging examination revealed a pedunculated tumor on the deltoid muscle on T2-weighted images. The normal range of CYFRA21-1 is >3.5 ng/ml. Computed tomography revealed metastasis to the neck, subclavicular and mediastinal lymph nodes.

On histopathological examination, tumor nests were identified in the entire thickness of the dermis. The tumor nests were continuous with the epidermis and were composed of poorly differentiated atypical squamous cells exhibiting high-grade malignancy, with mitotic figures and multinuclear cells (Fig. 2). lymph vessels invaded by poorly differentiated cutaneous SCC cells were also identified (Fig. 3).

Figure 2.

The tumor nests were composed of poorly differentiated atypical squamous cells, exhibiting high-grade malignancy, mitotic figures and multinuclear cells.

Figure 3.

Poorly differentiated cutaneous squamous cell carcinoma cells were observed in lymph vessels.

Based on the abovementioned clinical and histopathological findings, the diagnosis was cT3N2M1 (stage IV) poorly differentiated primary cutaneous SCC, metastatic to the regional lymph nodes (left axilla, neck and mediastinum).

The tumor was widely excised, with partial excision of the deltoid and trapezius muscles. Grafting with a latissimus dorsi flap was performed with axillary lymph node dissection. three cycles of postoperative chemotherapy with pepleomycin sulfate (a total of 85 mg) were administered. Following surgery, the level of CYFRA21-1 was significantly reduced. Further treatment was not performed, and the patient's current condition is not known as there were no follow-up hospital visits.

On immunohistochemical examination for keratin expression, the labeled streptavidin-biotin (LSAB) method was used (Dako, Carpinteria, CA, USA). The mouse anti-human keratin antibodies used in this study were as previously described (3): 34βB4 (K1; dilution 1:50), LP5K (K7; dilution 1:10), LP3K (K8; dilution 1:50), HP1 (K10; dilution 1:50), LL002 (K14; dilution 1:200), LHK15 (K15; dilution 1:40), LL025 (K16; dilution 1:20), E3 (K17; dilution 1:25), 5D3 (K18; dilution 1:20) and b170 (K19; dilution 1:100), all from Novocastra Laboratories Ltd., Newcastle upon Tyne, UK. The LSAB method was applied according to the manufacturer's instructions, as previously reported (3). K19 was significantly expressed in tumor cells (Fig. 4). K7 was weakly expressed in tumor nests. K8, K18 and the other keratins were not expressed in tumor cells.

Figure 4.

Keratin 19 was strongly expressed in tumor cells.

Patient's written informed consent was obtained for publication of this case study and the accompanying images.

Discussion

Keratins are the most diverse intermediate filaments, and may be used as markers of epithelial tumors, stage of differentiation and origin of epithelial tumors. There are a total of 54 human functional keratin genes (4).

K19 is the smallest keratin, with a molecular weight of 40 kd. The CYFRA21-1 circulating fragment is a marker of K19. In normal skin, K19 is present in the outermost cells of the hair follicle and in simple ductal epithelia (4); it is also found in lung adenocarcinoma and SCC (5).

As regards keratin expression in cutaneous SCC, stratified differentiated keratins (K1 and K10) are commonly detected in well-differentiated SCC, whereas simple epithelial keratins (K7, K8, K18 and K19) are detected in poorly differentiated SCC. These keratins are involved in tumor invasion and epithelial-mesenchymal interactions (6).

As regards elevated CYFRA21-1 levels in primary cutaneous carcinoma, two cases of eccrine porocarcinoma were previously reported (7).

K19 is present in the ductal cells of eccrine sweat glands. Therefore, the presence of K19 in eccrine sweat glands may be reflected in elevated CYFRA21-1 in eccrine porocarcinoma. To the best of our knowledge, no previous cases of cutaneous scc with elevated CYFRA21-1 have been reported. K19 is not present in the normal epidermis. Although K19 expression was not detected in blood vessels, we hypothesized that K19 in tumors is lysed by protease, resulting in spreading in the tissue, lymph vessels and lymph nodes. Subsequently, K19 enters blood vessels and is identified as elevated CYFRA21-1, a soluble cytokeratin fragment. In our case, CYFRA21-1 level was decreased following surgery. This result may reflect the clinical prognosis of the tumor. However, further similar cases should be accumulated in the future.

In summary, we reported a case of K19-positive cutaneous SCC with elevated serum CYFRA21-1 level. CYFRA21-1 level may reflect the clinical course of cutaneous SCC and it may be a marker of primary poorly differentiated cutaneous scc, useful in the diagnosis and as an indicator of the clinical course.

References

1 

Moll R, Divo M and Langbein L: The human keratins: Biology and pathology. Histochem Cell Biol. 129:705–733. 2008. View Article : Google Scholar : PubMed/NCBI

2 

Ebert W, Bodenmüller H and Hölzel W: CYFRA 21-1-clinical applications and analytical requirements. Scand J Clin Lab Invest Suppl. 221:72–80. 1995. View Article : Google Scholar : PubMed/NCBI

3 

Kurokawa I, Nishijima S, Kusumoto K, Senzaki H, Shikata N and Tsubura A: Trichilemmoma: An immunohistochemical study of cytokeratins. Br J Dermatol. 149:99–104. 2003. View Article : Google Scholar : PubMed/NCBI

4 

Kurokawa I, Takahashi K, Moll I and Moll R: Expression of keratins in cutaneous epithelial tumors and related disorders - distribution and clinical significance. Exp Dermatol. 20:217–228. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Blobel GA, Moll R, Franke WW and Vogt-Moykopf I: Cytokeratins in normal lung and lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. Virchows Arch B Cell Pathol Incl Mol Pathol. 45:407–429. 1984. View Article : Google Scholar : PubMed/NCBI

6 

Markey AC, Lane EB, Churchill LJ, MacDonald DM and Leigh IM: Expression of simple epithelial keratins 8 and 18 in epidermal neoplasia. J Invest Dermatol. 97:763–770. 1991. View Article : Google Scholar : PubMed/NCBI

7 

Onishi M, Yoshida A, Maeda F, et al: Two cases of eccrine porocarcinonma with high level of serum CYFRA. Skin Cancer. 29:38–42. 2014. View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ueda M, Yasuda M, Shibaoka Y, Kurokawa I, Kakuno A and Tsubura A: Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report. Mol Clin Oncol 4: 986-988, 2016.
APA
Ueda, M., Yasuda, M., Shibaoka, Y., Kurokawa, I., Kakuno, A., & Tsubura, A. (2016). Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report. Molecular and Clinical Oncology, 4, 986-988. https://doi.org/10.3892/mco.2016.834
MLA
Ueda, M., Yasuda, M., Shibaoka, Y., Kurokawa, I., Kakuno, A., Tsubura, A."Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report". Molecular and Clinical Oncology 4.6 (2016): 986-988.
Chicago
Ueda, M., Yasuda, M., Shibaoka, Y., Kurokawa, I., Kakuno, A., Tsubura, A."Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report". Molecular and Clinical Oncology 4, no. 6 (2016): 986-988. https://doi.org/10.3892/mco.2016.834
Copy and paste a formatted citation
x
Spandidos Publications style
Ueda M, Yasuda M, Shibaoka Y, Kurokawa I, Kakuno A and Tsubura A: Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report. Mol Clin Oncol 4: 986-988, 2016.
APA
Ueda, M., Yasuda, M., Shibaoka, Y., Kurokawa, I., Kakuno, A., & Tsubura, A. (2016). Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report. Molecular and Clinical Oncology, 4, 986-988. https://doi.org/10.3892/mco.2016.834
MLA
Ueda, M., Yasuda, M., Shibaoka, Y., Kurokawa, I., Kakuno, A., Tsubura, A."Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report". Molecular and Clinical Oncology 4.6 (2016): 986-988.
Chicago
Ueda, M., Yasuda, M., Shibaoka, Y., Kurokawa, I., Kakuno, A., Tsubura, A."Keratin 19‑positive cutaneous squamous cell carcinoma with elevated serum cytokeratin 19 fragment 21-1 level: A case report". Molecular and Clinical Oncology 4, no. 6 (2016): 986-988. https://doi.org/10.3892/mco.2016.834
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team